Myeloma

Postgraduate Haematology: Fifth Edition

Volumn , Issue , 2007, Pages 681-702

  Terpos, Evangelos ^a   Rahemtulla, Amin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Bone disease; Bone marrow microenvironment; Hypercalcaemia; Malignant plasma cell; Myeloma

Indexed keywords

EID: 84890683136     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987056.ch41     Document Type: Chapter

References (30)

1. Attal M, Harousseau JL, Facon T et al. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine 349: 2495-502.
2. Attal M, Harousseau JL, Stoppa AM et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New England Journal of Medicine 335: 91-7.
3. Bataille R, Harousseau JL (1997) Multiple Myeloma. New England Journal of Medicine 336: 1657-64.
4. Berenson JR, Hillner BE, Kyle RA et al. (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology 20: 3719-36.
5. Blade J, Samson D, Reece D et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. British Journal of Haematology 102: 1115-23.
6. Cavenagh JD, Oakervee H for the UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces (2003) Thalidomide in multiple myeloma: current status and future prospects. British Journal of Haematology 120: 18-26.
7. Child JA, Morgan GJ, Davies FE et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine 348: 1875-83.
8. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R (2000) Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 96: 2037-44.
9. Durie BGM, Kyle RA, Belch A et al. (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Haematology Journal 4: 379-98.
10. Gahrton G, Svensson H, Cavo M et al. (2001) Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. British Journal of Haematology 113: 209-16.
11. Greipp PR, San Miguel JF, Fonseca R et al. (2003) Development of an International Prognostic Index (IPI) for myeloma: report of the International Myeloma Working Group. The Hematology Journal 4 (Suppl 1): S42-S44.
12. Harousseau JL (2002) High-dose therapy in multiple myeloma. Annals of Oncology 13 (Suppl 4): 49-54.
13. Hayashi T, Hideshima T, Anderson KC (2003) Novel therapies for multiple myeloma. British Journal of Haematology 120: 10-17.
14. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
15. Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer 2: 175-87.
16. Kumar A, Loughran T, Alsina M et al. (2003) Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncology 4: 293-304.
17. Kyle RA, Therneau TM, Rajkumar SV et al. (2002) A long-term study of prognosis in monoclonal gammopathies of undetermined significance. New England Journal of Medicine 346: 564-9.
18. Moreau P, Facon T, Attal M et al. (2002) Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intregroupe Francophone du Myelome 9502 randomized trial. Blood 99: 731-5.
19. Myeloma Trialists' Collaborative Group (1998) Combination chemotherapy vs. melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. Journal of Clinical Oncology 16: 3832-42.
20. Myeloma Trialists' Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. British Journal of Haematology 113: 1020-34.
21. Rajkumar SV, Kyle RA, Gertz MA (2002) Myeloma and the newly diagnosed patient: a focus on treatment and management. Seminars in Oncology 29 (6 Suppl 17): 5-10.
22. Rawstron AC, Davies FE, DasGupta R et al. (2002) Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 100: 3095-100.
23. Riccardi A, Mora O, Tinelli C et al. (2000) Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. British Journal of Cancer 82: 1254-60.
24. Richardson PG, Barlogie B, Berenson J et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine 348: 2609-17.
25. Singhal S, Mehta J, Desikan R et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine 341: 1565-71.
26. Terpos E, Szydlo R, Apperley JF et al. (2003) Soluble receptor activator of nuclear factor kappa-B ligand/osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064-9.
27. Terpos E, Politou M, Rahemtulla A (2003) New insights into the pathophysiology and management of bone disease in multiple myeloma. British Journal of Haematology 123: 758-69.
28. Tian E, Zhan F, Walker R et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. New England Journal of Medicine 349: 2483-94.
29. UK Myeloma Forum Guidelines Working Group (2001) Guidelines on the diagnosis and management of multiple myeloma. British Journal of Haematology 115: 522-40.
30. UK Myeloma Forum AL Amyloidosis Guidelines Working Group (2004) Guidelines on the diagnosis and management of AL amyloidosis. British Journal of Haematology 125: 671-700.